Harmony Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Harmony Biosciences (HRMY) Tops Q4 EPS by 16c, Revenues Beat
March 25, 2021 8:01 AM EDTHarmony Biosciences (NASDAQ: HRMY) reported Q4 EPS of $0.25, $0.16 better than the analyst estimate of $0.09. Revenue for the quarter came in at $56.3 million versus the consensus estimate of $51.85 million.
Harmony achieved many milestones during 2020 and has entered 2021 well positioned to advance our strategic objectives, stated John C. Jacobs, President and Chief Executive... More
